Rakuten Investment Management Inc. Makes New Investment in Edwards Lifesciences Corporation $EW

Rakuten Investment Management Inc. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, Holdings Channel reports. The institutional investor bought 9,265 shares of the medical research company’s stock, valued at approximately $721,000.

Several other hedge funds also recently modified their holdings of the stock. Norges Bank purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares in the last quarter. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after purchasing an additional 1,584,958 shares during the last quarter. Finally, Holocene Advisors LP grew its position in Edwards Lifesciences by 35.2% in the 2nd quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock worth $367,898,000 after purchasing an additional 1,223,460 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE EW opened at $83.70 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The stock has a market capitalization of $48.57 billion, a PE ratio of 36.08, a P/E/G ratio of 3.19 and a beta of 0.95. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The business’s fifty day moving average price is $84.99 and its 200-day moving average price is $80.83.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Evercore ISI reissued an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. National Bankshares set a $92.00 price objective on Edwards Lifesciences in a research note on Friday, October 31st. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Finally, Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.